[Effects of sustained-release verapamil on hemodynamics and renal function of patients with moderate to severe chronic renal failure].
The effects of long-acting verapamil (240 mg/24 h) on blood pressure, systemic haemodynamic parameters, left ventricular function, renal blood flow, and blood and urinary chemistries were measured in hypertensive patients with moderate or severe chronic renal failure. The treatment was proposed for a 4-week period after a 2-week placebo period. In the 15 patients studied, lower arterial pressure resulted from decreased peripheral vascular resistances. Cardiac parameters were not found to change during treatment. The lowered blood pressure had non effect on glomerular filtration which remained unchanged throughout the 4-week treatment. Renal vascular resistances greatly decreased and renal blood flow increased significantly. No major change in blood or urine chemistries were seen excepting uric acid for which a significant decrease in the blood level correlated with significantly increased urinary excretion. Finally, the left ventricle function curves were unchanged as was the baroreceptor circuit. Long-acting verapamil was thus found to be effective and well tolerated in patients with chronic renal failure.
Schohn
D
D
Service de Néphrologie et d'Hémodialyse, CHRU, Strasbourg.
Maarek
M
M
Jahn
H
H
D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D010919:Placebos; D017595:Renal Plasma Flow / Q000187:drug effects; D014700:Verapamil / Q000494:pharmacology* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D010919:Placebos; D014700:Verapamil
Effets du vérapamil à libération prolongée sur l'hémodynamique et la fonction rénale de patients en insuffisance rénale chronique modérée à sévère.